JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

67%

33%

331 / 373 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. okt 2025, 17:40 UTC

Omandamised, ülevõtmised, äriostud

Orange to Buy Lorca's 50% Stake in MasOrange for $4.9 Billion

31. okt 2025, 23:09 UTC

Tulu

Review & Preview: October Surprise -- Barrons.com

31. okt 2025, 22:44 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31. okt 2025, 21:25 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Pfizer Says Novo Nordisk's Metsera Bid Won't Pass Antitrust Laws -- Market Talk

31. okt 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- Update

31. okt 2025, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Sues Metsera, Novo Nordisk, Claiming Novo Nordisk Takeover Offer Isn't Superior -- WSJ

31. okt 2025, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31. okt 2025, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Seeks Order Blocking Metsera From Terminating Its Merger Deal With Pfizer -- WSJ

31. okt 2025, 20:51 UTC

Omandamised, ülevõtmised, äriostud

Another Rare-Earth Stock Jumps on Government Deal -- Barrons.com

31. okt 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

31. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. okt 2025, 20:50 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

31. okt 2025, 20:46 UTC

Omandamised, ülevõtmised, äriostud

Pfizer: Files Lawsuit Against Metsera and Its Directors and Novo Nordisk for Breach of Merger Agreement

31. okt 2025, 20:22 UTC

Tulu

Amazon Stock Hits New Record. What Was So Good in Its Earnings Report. -- Barrons.com

31. okt 2025, 20:02 UTC

Tulu

Meta Faces a Sudden Reckoning. How Big Tech Earnings Are Reshaping the AI Race. -- Barrons.com

31. okt 2025, 19:55 UTC

Market Talk

Crude Futures Fall for Third Straight Month -- Market Talk

31. okt 2025, 19:54 UTC

Omandamised, ülevõtmised, äriostud

Pfizer: FTC Granted Early Termination of Waiting Period >PFE

31. okt 2025, 19:54 UTC

Omandamised, ülevõtmised, äriostud

Pfizer: Receives Early Clearance From FTC for Metsera Acquisition

31. okt 2025, 19:26 UTC

Market Talk

U.S. Natural Gas Rises on Winter Outlook, Strong LNG -- Market Talk

31. okt 2025, 18:30 UTC

Tulu

These Stocks Are Moving the Most Today: Amazon, Nvidia, Apple, Netflix, Exxon, DexCom, Coinbase, Reddit, Newell Brands, and More -- Barrons.com

31. okt 2025, 18:23 UTC

Market Talk

Gold Edges Lower for the Day, Closes October Positive -- Market Talk

31. okt 2025, 18:09 UTC

Tulu

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31. okt 2025, 18:08 UTC

Tulu

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31. okt 2025, 17:36 UTC

Market Talk

Grain Futures Shrug Off Stronger Dollar -- Market Talk

31. okt 2025, 17:31 UTC

Market Talk

U.S. Oil Rig Count Falls, Natural Gas Rig Count Rises -- Market Talk

31. okt 2025, 17:16 UTC

Omandamised, ülevõtmised, äriostud

Orange: Acquisition Likely Completed in First Half Next Year

31. okt 2025, 17:15 UTC

Omandamised, ülevõtmised, äriostud

Orange: Agreement Set to Be Signed By Year-Out

31. okt 2025, 17:14 UTC

Omandamised, ülevõtmised, äriostud

Orange: Acquisition Will Strengthen Position in Spain

31. okt 2025, 17:13 UTC

Omandamised, ülevõtmised, äriostud

Orange Will Be Sole Owner of Spain's MasOrange Following Acquisition of Lorca's Stake

31. okt 2025, 17:12 UTC

Omandamised, ülevõtmised, äriostud

Orange Reaches Deal to Buy Lorca's 50% Stake in MasOrange for EUR4.25B

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

331 / 373 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.